Oragenics Advances Phase IIa Trial Of ONP-002 For Concussion

Oragenics reported early progress in its Phase IIa trial of ONP-002 for mild traumatic brain injury, with two patients enrolled and eight study drug doses administered. The update is incremental and operational rather than outcome-driven, so it is unlikely to materially move shares absent efficacy or safety data.

Analysis

Oragenics reported early progress in its Phase IIa trial of ONP-002 for mild traumatic brain injury, with two patients enrolled and eight study drug doses administered. The update is incremental and operational rather than outcome-driven, so it is unlikely to materially move shares absent efficacy or safety data.